EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Marine Pharmacology in 2022–2023: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities, Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Alejandro M S Mayer iD, Veronica A Mayer, Michelle Swanson-Mungerson iD, Marsha L Pierce iD, Cai M Roberts iD, Abimael D Rodríguez, Fumiaki Nakamura iD, Orazio Taglialatela-Scafati iD

Marine Drugs · 09.04.2026 · 24 (4) · 133

DOI: 10.3390/md24040133 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Marine Drugs, online erschienen am 09.04.2026. Verfasst von Alejandro M S Mayer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA. Hauptthemen laut MEDLINE: Aquatic Organisms, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 303 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH-SC1 Award, Japan Society for the Promotion of Science, MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During 2022–2023, research groups from 40 nations contributed to the preclinical pharmacology of 173 structurally defined marine-derived compounds, unveiling innovative mechanisms of action. Peer-reviewed publications in the field of marine natural product pharmacology during 2022–2023 included mechanism-of-action studies with 43 compounds showing antibacterial, antifungal, antiprotozoal, antitubercular, and antiviral activity. Additional mechanism-of-action studies were reported for 74 marine compounds that exhibited antidiabetic and anti-inflammatory properties, as well as significant effects on both the immune and nervous systems. Finally, while 65 marine compounds revealed unique and diverse pharmacological mechanisms, further investigation will be required to determine whether they will contribute to a particular therapeutic category. Collectively, the pharmacology of 2022–2023 preclinical marine natural products demonstrated robust activity, offering both novel mechanistic insights and promising chemical scaffolds to enrich the 2026 marine pharmaceutical development pipeline (https://www.marinepharmacology.org/) which currently consists of 17 marine-derived pharmaceuticals approved for clinical use and 29 compounds in either Phase I, II or III of clinical pharmaceutical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aquatic OrganismsBiological ProductsHumansAnimalsHypoglycemic AgentsAntiviral AgentsAnti-Inflammatory AgentsAntifungal AgentsAntiprotozoal AgentsNervous SystemAntitubercular AgentsAnti-Bacterial AgentsImmune SystemDrug Development

Stichwörter der Autor:innen

drugmarinemechanismpharmaceuticalpharmacologypipelinepreclinicalreviewseatoxicology

Substanzen

Biological ProductsHypoglycemic AgentsAntiviral AgentsAnti-Inflammatory AgentsAntifungal AgentsAntiprotozoal AgentsAntitubercular AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
  • Department of Nursing Education, School of Nursing, Aurora University, 347 S. Gladstone Ave., Aurora, IL 60506, USA.
  • Department of Microbiology and Immunology, College of Graduate Studies, Midwestern University, 555 31st Street, Downers Grove, IL 60515, USA.
  • Molecular Sciences Research Center, University of Puerto Rico, 1390 Ponce de León Avenue, San Juan, PR 00926, USA.
  • Research Institute for Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan.
  • Department of Pharmacy, University of Naples Federico II, Via D. Montesano 49, I-80131 Napoli, Italy.

ORCID-Profile: Alejandro M S Mayer, Michelle Swanson-Mungerson, Marsha L Pierce, Cai M Roberts, Fumiaki Nakamura, Orazio Taglialatela-Scafati

Förderung

  • NIH-SC1 Award
  • Japan Society for the Promotion of Science
  • MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases

Zitieren

APA

Mayer, A. M. S., Mayer, V. A., Swanson-Mungerson, M., Pierce, M. L., Roberts, C. M., Rodríguez, A. D., Nakamura, F., & Taglialatela-Scafati, O. (2026). Marine Pharmacology in 2022–2023: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities, Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Marine Drugs, 24(4), 133. https://doi.org/10.3390/md24040133

Vancouver

Mayer AMS, Mayer VA, Swanson-Mungerson M, Pierce ML, Roberts CM, Rodríguez AD, et al. Marine Pharmacology in 2022–2023: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities, Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action. Marine Drugs. 2026;24(4):133. doi:10.3390/md24040133

BibTeX
@article{Mayer2026,
  author = {Mayer, Alejandro M S and Mayer, Veronica A and Swanson-Mungerson, Michelle and Pierce, Marsha L and Roberts, Cai M and Rodríguez, Abimael D and Nakamura, Fumiaki and Taglialatela-Scafati, Orazio},
  title = {Marine Pharmacology in 2022–2023: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities, Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action},
  journal = {Marine Drugs},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {133},
  doi = {10.3390/md24040133}
}
Kostenlos starten →